Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implications

Catheterization and Cardiovascular Interventions

Volumn 83, Issue 6, 2014, Pages

  Rocha Singh, Krishna J ^a   Zeller, Thomas ^b   Jaff, Michael R ^c  

^a ST JOHN'S HOSPITAL   (United States)

^b UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

atherosclerosis; peripheral artery disease; vascular calcification

Indexed keywords

CALCIMIMETIC AGENT; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEMINERALIZATION; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ECHOGRAPHY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; MINERALIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL CALCIFICATION; PERIPHERAL ARTERIAL CALCIUM SCORING SYSTEM; PREVALENCE; PULSE WAVE; SCORING SYSTEM; ANIMAL; LEG; MONCKEBERG MEDIAL CALCIFIC SCLEROSIS; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VASCULAR CALCIFICATION; VASCULARIZATION;

ANIMALS; HUMANS; LOWER EXTREMITY; MONCKEBERG MEDIAL CALCIFIC SCLEROSIS; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VASCULAR CALCIFICATION;

EID: 84899465482     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25387     Document Type: Article

References (51)

1. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khana R,. Vascular ossification-Calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-Calcific uremic arteriolopathy: The emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005; 4: 4.
2. Sage A, Tintut Y, Demer L,. Regulatory mechanisms in vascular calcification Nat Rev Cardiol 2010; 7: 528-536.
3. Karwowski W, Naumnik B, Szczepański M, Myśliwiec M,. The mechanism of vascular calcification-A systematic review. Med Sci Monit 2012; 18: RA1-RA11.
4. Nitta K,. Vascular calcification in patients with chronic kidney disease. Ther Apher Dial 2011; 15: 513-521.
5. Giachelli CM,. Vascular calcification mechanisms. J Am Soc Nephrol. 2004; 15: 2959-2964.
6. Abedin M, Tintut Y, Demer L,. Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-1170.
7. Shao JS, Cheng SL, Sadhu J, Towler DA,. Inflammation and the osteogenic regulation of vascular calcification: A review and perspective. Hypertension 2010; 55: 579-592.
8. Marso SP, Hiatt WR,. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47: 921-929.
9. Pyörälä K, Laakso M, Uusitupa M,. Diabetes and atherosclerosis: An epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
10. Edmonds ME, Morrison N, Laws JW, Watkins PJ,. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed) 1982; 284: 928-930.
11. Mizobuchi M, Towler D, Slatopolsky E,. Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-1464.
12. Amann K,. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1599-1605.
13. Moe SM, Chen NX,. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567.
14. 2+ homeostasis disorders. Molecules 2010; 15: 7167-7187.
15. Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA,. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediat Inflamm 2010; 2010: 453892.
16. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM,. Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
17. Bowman M, McNally E,. Genetic pathways in vascular calcification. Trends Cardiovasc Med 2012; 22: 93-98.
18. Golomb BA, Dang TT, Criqui MH,. Peripheral arterial disease: Morbidity and mortality implications. Circulation 2006; 114: 688-699.
19. Selvin E, Erlinger TP,. Prevalence of and risk factors for peripheral arterial disease in the United States. Results from the National Health and Nutrition Examination Survery, 1999-2000. Circulation 2004; 110: 728-743.
20. Belch JJ, Topol EJ, Agnelli F, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR, 3rd, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA,;for the Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: A call to action. Arch Intern Med 2003; 163: 884-892.
21. Hirsch AT, Criqui MH, Treat-Jacobsen D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR,. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
22. Allison MA, Criqui MH, Wright M,. Patterns and risk factors for systemic calcified atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 331-336.
23. Rifkin DE, Ix JH, Wassel CL, Criqui MH, Allison MA,. Renal artery calcification and mortality among clinically asymptomatic adults. J Am Coll Cardiol 2012; 60: 1079-1085.
24. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA,. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society foe Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease). Circulation 2006; 113: e463-e654.
25. Josephs SC, Rowley HA, Rubin GD,; for Writing Group 3. Atherosclerotic Peripheral Vascular Disease Symposium II. Vascular magnetic resonance and computed tomographic imaging. Circulation 2008; 118: 2837-2844.
26. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ,. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: A study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant 2004; 19: 2307-2312.
27. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130.
28. Weinberg I, Giri J, Calfon M, Hawkins BM, Weinberg MD, Margey R, Hannon K, Schainfeld RM, Jaff MR,. Anatomic correlates of supra-normal ankle brachial indices. Catheter Cardiovasc Intervent 2013; 81: 1025-1030.
29. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC,. Association of bone density, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835.
30. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P,. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
31. Chertow GM, Burke SK, Raggi P,; for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
32. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalatar-Zadeh K, Ahmadzadeh S,. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: A randomized controlled trial. Am J Kidney Dis 2012; 59: 58-66.
33. Garcia-Lopes MG, Pillar R, Kamimura MA, Rocha LA, Canziani ME, Carvalho AB, Cuppari L,. Cholecalciferol supplementation in chronic kidney disease: Restoration of vitamin D status and impact on parathyroid hormone. Ann Nutr Metab 2012; 61: 74-82.
34. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S,. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-382.
35. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J,;for the ADVANCE study group. The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339.
36. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM,. Effects of the calcimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
37. Sianos G, Morel MA, Kappetein A, Morice M, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell M, Mohr F, Serruys P,. The SYNTAX Score: An angiographic tool grading the complexity of coronary artery disease. Eurointervention 2005; 1: 219-227.
38. Capek P, McLean GK, Berkowitz HD,. Femoropopliteal angioplasty: Factors influencing long-term success. Circulation 1991; 83: Suppl 2: I70-I80.
39. Bausback Y, Botsios S, Flux J, Werner M, Schuster J, Aithal J, Varcoe R, Bräunlich S, Ulrich M, Scheinert D, Schmidt A,. Outback catheter for femoropopliteal occlusions: immediate and long-term results. J Endovasc Ther 2011; 18: 13-21.
40. Scheinert D, Grummt L, Piorkowski M, Sax J, Scheinert S, Ulrich M, Werner M, Bausback Y, Braunlich S, Schmidt A,. A novel self-expanding interwoven nitinol stent for complex femoropopliteal lesions: 24-month results of the SUPERA SFA registry. J Endovasc Ther 2011; 18: 745-752.
41. Claire D, Roberts D,. Treatment of severely calcified femoropopliteal lesions with plaque excision and embolic protection: DEFINITIVE Ca++. J Vasc Interv Radiol 2011; 22: 1785.e2.
42. Das T, Mustapha J, Indes J, Vorhies R, Beasley R, Doshi N, Adams G,. Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremity: The CONFIRM series, a prospective, multicenter registry. Catheter Cardiovasc Interv 2014; 83: 115-122.
43. Kim J, Ahanchi S, Panneton J,. Identifying the target lesions for 245 laser angioplasty cases and a review of the literature. Vasc Endovasc Surg 2012; 46: 640-647.
44. Zeller T, Krankenberg H, Steinkamp H, Rastan A, Sixt S, Sievert H, Minar E, Bosier M, Peeters P, Balzer O, Gray W, Tubler T, Wissgott C, Schwarzwalder U, Scheinert D,. One-year outcome of percutaneous rotational percutaneous atherectomy with aspiration in infrainginual peripheral arterial occlusive disease: The multicenter Pathway PVD Trial. J Endovasc Ther 2009; 16: 653-662.
45. Shrikhande G, McKinsey J,. Use and abuse of atherectomy: Where should it be used? J Vasc Surg 2008; 21: 204-209.
46. Todd K, Ahanchi S, Maurer C, Kim J, Chipman C, Panneton J,. Atherectomy offers no advantage over balloon angioplasty in tibial interventions for critical limb ischemia. J Vasc Surg 2013; 58: 941-948.
47. Fanelli F,. Is There a Role for DEB in Calcified Arteries? Leipzig, Germany: LINC Interventional Congress; 2013.
48. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003; 42: 1415-1420.
49. Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: Comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 2006; 240: 411-418.
50. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ,. Compensatory enlargement of human atherosclerotic coronary artery disease. N Engl J Med 1987; 316: 1371-1375.
51. Cioppa A, Stabile E, Popusoi G, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results. Cardiovasc Revasc Med 2012; 13: 219-223.